BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed ENTA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:e546e2762fdc02a89c1f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ENTA P2 readout (est.): A Phase 2 Study to Investigate the Efficacy
  and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months
  of Age Infected With Respiratory Syncytial Virus
DESCRIPTION:A Phase 2 Study to Investigate the Efficacy and Safety of Zelic
 apavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected Wit
 h Respiratory Syncytial Virus\nNCT07482657 | PHASE2 | RECRUITING | sponsor
 : Enanta Pharmaceuticals\, Inc\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nTicker ENTA (confidence 0.9)\nSource: https://clinicaltrials.gov
 /study/NCT07482657\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07482657
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
